Viatris (VTRS) Other Accumulated Expenses (2019 - 2026)
Viatris' (VTRS) quarterly Other Accumulated Expenses came in at $3.1 billion in Q1 2026, down 13.77% year-on-year from $3.6 billion in Q1 2025, and down 4.66% quarter-over-quarter from $3.3 billion in Q4 2025.
Viatris (VTRS) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Viatris' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.1 billion for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses fell 13.77% year-over-year to $3.1 billion in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 13.77% decrease from a year earlier, with the FY2025 full-year figure at $3.3 billion, down 11.86% from the prior year.
- Other Accumulated Expenses slipped to $3.1 billion in Q1 2026 per VTRS's latest filing, from $3.3 billion in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $4.4 billion in Q1 2022 and bottomed at $3.0 billion in Q2 2023.
- The 5-year median for Other Accumulated Expenses is $3.4 billion (2022), against an average of $3.5 billion.
- Across the five-year window, Other Accumulated Expenses declined 27.87% in 2023 and advanced 16.27% in 2024, its largest moves.
- Year by year, Other Accumulated Expenses stood at $3.4 billion in 2022, then decreased by 1.37% to $3.4 billion in 2023, then advanced by 9.75% to $3.7 billion in 2024, then slipped by 11.86% to $3.3 billion in 2025, then decreased by 4.66% to $3.1 billion in 2026.
- Per Business Quant, the three latest VTRS Other Accumulated Expenses figures stand at $3.1 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.13 Bn |
| Dec 31, 2025 | 3.28 Bn |
| Sep 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.67 Bn |
| Mar 31, 2025 | 3.63 Bn |
| Dec 31, 2024 | 3.72 Bn |
| Sep 30, 2024 | 3.86 Bn |
| Jun 30, 2024 | 3.23 Bn |
| Mar 31, 2024 | 3.28 Bn |
| Dec 31, 2023 | 3.39 Bn |
| Sep 30, 2023 | 3.32 Bn |
| Jun 30, 2023 | 3.05 Bn |
| Mar 31, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.44 Bn |
| Sep 30, 2022 | 3.50 Bn |
| Jun 30, 2022 | 3.81 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 4.62 Bn |
| Sep 30, 2021 | 4.63 Bn |
| Jun 30, 2021 | 4.21 Bn |